NCT05514132 2026-03-09
A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
AstraZeneca
Pyxis Oncology, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
AstraZeneca
RemeGen Co., Ltd.
Shandong Boan Biotechnology Co., Ltd